• 1
    Laliberte F., Han Y., Govindarajan A., et al. Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 2000;39:64496458.
  • 2
    Torphy TJ. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351370.
  • 3
    Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here Drugs 2000;59:193212.
  • 4
    Leguillette R., Désévaux C., Lavoie JP. Effects of pentoxifylline on pulmonary function and results of cytologic examination of bronchoalveolar lavage fluid in horses with recurrent airway obstruction. Am J Vet Res 2002;63:459463.
  • 5
    Rickards KJ, Page CP, Lees P., Cunningham FM. Phosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease. Vet Immunol Immunopathol 2000;76:319330.
  • 6
    Rickards KJ, Page CP, Cunningham FM. Allergen challenge alters lymphocyte phosphodiesterase activity in horses with heaves. Pulm Pharmacol Ther 2004;17:163172.
  • 7
    Brideau C., Van Staden C., Styhler A., et al. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay. Br J Pharmacol 1999;126:979988.
  • 8
    Thomas PS. Tumour necrosis factor-alpha: The role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001;79:132140.
    Direct Link:
  • 9
    Marr KA, Lees P., Page CP, Cunningham FM. Inhaled leukotrienes cause bronchoconstriction and neutrophil accumulation in horses. Res Vet Sci 1998;64:219224.
  • 10
    Lavoie JP, Leguillette R., Pasloske K., et al. Comparison of dexamethasone and the LTD4 receptor antagonist L-708,738 on lung function and airway cytology in heaves. Am J Vet Res 2002;63:579585.
  • 11
    Frenette R., Blouin M., Brideau C., et al. Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters. Bioorg Med Chem Lett 2002;12:30093013.
  • 12
    Baskett A., Barton MH, Norton N., et al. Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. Am J Vet Res 1997;58:12911299.
  • 13
    Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63:25752594.
  • 14
    Souness JE, Aldous D., Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000;47:127162.
  • 15
    McKiernan BC, Koritz GD. Plasma theophylline concentration and lung function in ponies with recurrent obstructive lung disease. Equine Vet J 1990;22:194197.
  • 16
    Bundschuh DS, Eltze M., Barsig J., et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280290.
  • 17
    Wang P., Wu P., Ohleth KM, et al. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 1999;56:170174.
  • 18
    Gantner F., Tenor H., Gekeler V., et al. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study. J Allergy Clin Immunol 1997;100:527535.
  • 19
    Nielson CP, Vestal RE, Sturm RJ, Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 1990;86:801808.
  • 20
    Chilcoat CD, Rowlingson KA, Jones SL. The effects of cAMP modulation upon the adhesion and respiratory burst activity of immune complex-stimulated equine neutrophils. Vet Immunol Immunopathol 2002;88:6577.
  • 21
    Spond J., Chapman R., Fine J., et al. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 2001;14:157164.
  • 22
    Franchini M., Gilli U., Akens MK, et al. The role of neutrophil chemotactic cytokines in the pathogenesis of equine chronic obstructive pulmonary disease (COPD). Vet Immunol Immunopathol 1998;66:5365.
  • 23
    Lamblin C., Gosset P., Tillie-Leblond I., et al. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med 1998;157:394402.
  • 24
    Claveau D., Chen SL, O'Keefe S., et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141[4-[2-(3,4-bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hex-afluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004;310:752760.
  • 25
    Rabe KF, Tenor H., Dent G., et al. Phosphodiesterase isozymes modulating inherent tone in human airways: Identification and characterization. Am J Physiol 1993;264:L458L464.
  • 26
    Torphy TJ, Undem BJ, Cieslinski LB, et al. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther 1993;265:12131223.
  • 27
    Mehats C., Jin SL, Wahlstrom J., et al. PDE4D plays a critical role in the control of airway smooth muscle contraction. Faseb J 2003;17:18311841.
  • 28
    Kanehiro A., Ikemura T., Makela MJ, et al. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 2001;163:173184.
  • 29
    Underwood DC, Osborn RR, Novak LB, et al. Inhibition of Antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, Rolipram. J Pharmacol Exp Ther 1993;266:306313.
  • 30
    Muise ES, Chute IC, Claveau D., et al. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. Biochem Pharmacol 2002;63:15271535.
  • 31
    Schmidt DT, Watson N., Dent G., et al. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol 2000;131:16071618.
  • 32
    Robinson NE. International Workshop on Equine Chronic Airway Disease. Michigan State University, 16–18 June 2000. Equine Vet J 2001; 33: 519.
  • 33
    Blease K., Burke-Gaffney A., Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 1998;124:229237.